[Tubulin and its related signal].
Antimitotic agents are expected to exert the high antitumor potency on various solid tumors. One of the determining factors for the sensitivity/resistance to these antimitotic agents is the status of the tubulin to which these drugs bind. Quantitative and qualitative changes such as gene mutations of the beta-tubulin were suspected to be major determining factors. Microtubule-associated proteins and the related signaling by the mitogen-activated protein kinase cascade are also considered to be factors influencing the sensitivity/resistance of the tumor cells to the antimitotic agents. These are promising targets for development of new antimitotic agents.